par Tsukamoto, Katsura;Cnop, Miriam
;Mori, Daichi;Kume, Shoen;Anazawa, Takayuki;Doi, Masako;Chikazawa, Kazuhiko;Matsumaru, Naoki
Référence Therapeutic Innovation and Regulatory Science, 53, 4, page (535-541)
Publication Publié, 2019-07-01
;Mori, Daichi;Kume, Shoen;Anazawa, Takayuki;Doi, Masako;Chikazawa, Kazuhiko;Matsumaru, NaokiRéférence Therapeutic Innovation and Regulatory Science, 53, 4, page (535-541)
Publication Publié, 2019-07-01
Article révisé par les pairs
| Titre: |
|
| Auteur: | Tsukamoto, Katsura; Cnop, Miriam; Mori, Daichi; Kume, Shoen; Anazawa, Takayuki; Doi, Masako; Chikazawa, Kazuhiko; Matsumaru, Naoki |
| Informations sur la publication: | Therapeutic Innovation and Regulatory Science, 53, 4, page (535-541) |
| Statut de publication: | Publié, 2019-07-01 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| Mots-clés: | pharmaceutical approval |
| pharmacotherapy | |
| regulatory guidance | |
| type 1 diabetes mellitus | |
| type 2 diabetes mellitus | |
| MeSH keywords: | Diabetes Mellitus -- drug therapy -- prevention & control |
| Drug Development -- legislation & jurisprudence | |
| European Union | |
| Government Regulation | |
| Humans | |
| Hypoglycemic Agents -- therapeutic use | |
| Japan | |
| United States | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:2168-4790 |
| info:doi/10.1177/2168479018795854 | |
| info:pmid/30176740 |



